Abstract
Angiogenesis is one of the key rate limiting factors in tumor growth. The concept of antiangiogenic therapy was first considered over 50 years ago but the first antiangiogenic therapy for breast cancer was only given regulatory status in 2008. A large number, and diverse range, of therapeutic agents are, however, currently in development for use in breast cancer with results suggesting great promise. Some of these agents directly target molecules in the angiogenic cascade and others have secondary antiangiogenic effects as a consequence of inhibition of target molecules that are not directly involved in the angiogenic process. Here some of the agents currently under development are discussed together with other, currently hypothetical, targets.
Keywords: Angiogenic Cascade, Breast Cancer, Hypothetical Targets
Related Journals
Current Drug Delivery
Current Bioactive Compounds
Current Drug Safety
Reviews on Recent Clinical Trials
Drug Delivery Letters
Recent Advances in Drug Delivery and Formulation
Recent Advances in Anti-Infective Drug Discovery
Drug Metabolism and Bioanalysis Letters
Applied Drug Research, Clinical Trials and Regulatory Affairs
Current Drug Targets - Inflammation & Allergy
Related Books
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Biopolymers In Drug Delivery: Recent Advances and Challenges
Chemoinformatics: Directions Toward Combating Neglected Diseases
Current Advances in Drug Delivery Through Fast Dissolving/Disintegrating Dosage Forms
Current Technologies To Increase The Transdermal Delivery Of Drugs